Disease Info Card

Tyrosinemia, Type I

Information about Tyrosinemia, Type I: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Tyrosinemia, Type I

Most recent studies have shown that Tyrosinemia, Type I shares some biological mechanisms with acidemia, carcinoma, hepatomegaly, hereditary-diseases, inborn-errors-of-metabolism, liver-carcinoma, liver-cirrhosis, liver-damage, liver-diseases, liver-failure, liver-failure-acute, liver-neoplasms, malignant-neoplasm-of-liver, malignant-neoplasms, metabolic-diseases, neoplasms, propionic-acidemia, renal-tubular-disorder, rickets, tyrosinemias.

Among the many pathways, these few ones have gauged particular interests from scientists studying Tyrosinemia, Type I, and have been seen in publications frequently: Aging, Cell Cycle, Cell Cycle Arrest, Cell Death, Dna Repair, Excretion, Fatty Acid Oxidation, Gluconeogenesis, Liver Regeneration, Localization, Pathogenesis, Pigmentation, Programmed Cell Death, Regeneration, Response To Phenylalanine, Reverse Transcription, Translation, Transport, Transposition, Urea Cycle

Quite a number of genes have been found to play important roles in Tyrosinemia, Type I, such as AFP, ALAD, CASP3, CYCS, F2, FAH, FAM126A, FANCA, GNMT, GSTZ1, HGD, HPD, LRP2, MCF2L, OTC, QPCT, TRIM26, TYR. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.